Changesin bone mineral densityafter96weeksoftreatment with atazanavir/ritonavir or lopinavir/ritonavir plus tenofovir df/emtricitabine in treatment-naive patients with hiv-1 infection: The castle body composition substudy

Journal of Acquired Immune Deficiency Syndromes

Volumn 68, Issue 1, 2015, Pages 40-45

  Moyle, Graeme J ^a   Hardy, Hélene ^b   Farajallah, Awny ^b   McGrath, St John ^c   Kaplita, Stephen ^a   Ward, Douglas ^b  

^a CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

^b BRISTOL MYERS SQUIBB   (United States)

^c Dupont Circle Physicians Group   (United States)

Author keywords

Atazanavir; Body mass index; Bone mineral density; Lopinavir; Ritonavir

Indexed keywords

ATAZANAVIR PLUS RITONAVIR; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; LOPINAVIR PLUS RITONAVIR; VIRUS RNA; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ATAZANAVIR; LOPINAVIR; OLIGOPEPTIDE; PYRIDINE DERIVATIVE; RITONAVIR;

ADULT; ANTIVIRAL THERAPY; ARM; ARTICLE; BODY REGIONS; BONE DENSITY; CD4 LYMPHOCYTE COUNT; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; LEG; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); SIDE EFFECT; TREATMENT DURATION; TRUNK; VIRUS LOAD; BODY COMPOSITION; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; MULTIVARIATE ANALYSIS; PATHOPHYSIOLOGY; PHOTON ABSORPTIOMETRY;

ABSORPTIOMETRY, PHOTON; ANTI-HIV AGENTS; BODY COMPOSITION; BONE DENSITY; HIV INFECTIONS; HIV-1; HUMANS; LOPINAVIR; MULTIVARIATE ANALYSIS; OLIGOPEPTIDES; PYRIDINES; RITONAVIR;

EID: 84919360257     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0000000000000383     Document Type: Article

References (38)

1. Bolland MJ, Wang TK, Grey A, et al. Stable bone density in HAARTtreated individuals with HIV: a meta-analysis. J Clin Endocrinol Metab. 2011;96:2721-2731
2. Brown TT, Qaqish RB. Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review. AIDS. 2006;20: 2165-2174
3. Zhao H, Goetz MB. Complications of HIV infection in an ageing population: challenges in managing older patients on long-term combination antiretroviral therapy. J Antimicrob Chemother. 2011;66:1210-1214
4. Cassetti I, Madruga JV, Suleiman JM, et al. The safety and efficacy of tenofovir DF in combination with lamivudine and efavirenz through 6 years in antiretroviral-naive HIV-1-infected patients. HIV Clin Trials. 2007;8:164-172
5. Duvivier C, Kolta S, Assoumou L, et al. Greater decrease in bone mineral density with protease inhibitor regimens compared with nonnucleoside reverse transcriptase inhibitor regimens in HIV-1 infected naive patients. AIDS. 2009;23:817-824
6. Hansen AB, Obel N, Nielsen H, et al. Bone mineral density changes in protease inhibitor-sparing vs. nucleoside reverse transcriptase inhibitorsparing highly active antiretroviral therapy: data from a randomized trial. HIV Med. 2011;12:157-165
7. Rivas P, Gorgolas M, Garcia-Delgado R, et al. Evolution of bone mineral density in AIDS patients on treatment with zidovudine/lamivudine plus abacavir or lopinavir/ritonavir. HIV Med. 2008;9:89-95
8. Stellbrink HJ, Orkin C, Arribas JR, et al. Comparison of changes in bone density and turnover with abacavir-lamivudine versus tenofoviremtricitabine in HIV-infected adults: 48-week results from the ASSERT study. Clin Infect Dis. 2010;51:963-972
9. van Vonderen MG, Lips P, van Agtmael MA, et al. First line zidovudine/lamivudine/lopinavir/ritonavir leads to greater bone loss compared to nevirapine/lopinavir/ritonavir. AIDS. 2009;23:1367-1376
10. Triant VA, Brown TT, Lee H, et al. Fracture prevalence among human immunodeficiency virus (HIV)-infected versus non-HIV-infected patients in a large U.S. healthcare system. J Clin Endocrinol Metab. 2008;93:3499-3504
11. Brown TT, McComsey GA, King MS, et al. Loss of bone mineral density after antiretroviral therapy initiation, independent of antiretroviral regimen. J Acquir Immune Defic Syndr. 2009;51:554-561
12. Amorosa V, Tebas P. Bone disease and HIV infection. Clin Infect Dis. 2006;42:108-114
13. Walker Harris V, Brown TT. Bone loss in the HIV-infected patient: evidence, clinical implications, and treatment strategies. J Infect Dis. 2012;205(suppl 3):S391-S398
14. Gallant JE, Staszewski S, Pozniak AL, et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviralnaive patients: a 3-year randomized trial. JAMA. 2004;292:191-201
15. Woodward CL, Hall AM, Williams IG, et al. Tenofovir-associated renal and bone toxicity. HIV Med. 2009;10:482-487
16. Borderi M, Gibellini D, Vescini F, et al. Metabolic bone disease in HIV infection. AIDS. 2009;23:1297-1310
17. Pan G, Yang Z, Ballinger SW, et al. Pathogenesis of osteopenia/osteoporosis induced by highly active anti-retroviral therapy for AIDS. Ann N Y Acad Sci. 2006;1068:297-308
18. Franco JM, Rubio A, Martinez-Moya M, et al. T-cell repopulation and thymic volume in HIV-1-infected adult patients after highly active antiretroviral therapy. Blood. 2002;99:3702-3706
19. Ofotokun I, Weitzmann MN. HIV and bone metabolism. Discov Med. 2011;11:385-393
20. Arora S, Agrawal M, Sun L, et al. HIV and bone loss. Curr Osteoporos Rep. 2010;8:219-226
21. Molina JM, Andrade-Villanueva J, Echevarria J, et al. Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-nave HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study. Lancet. 2008;372:646-655
22. The International Society for Clinical Densitometry. 2013 ISCD Official Positions-Adult. Available at: http://www.iscd.org/official-positions/2013-iscd-official-positions-adult/. Accessed August 08, 2014
23. McComsey GA, Kitch D, Daar ES, et al. Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: Aids Clinical Trials Group A5224s, a substudy of ACTG A5202. J Infect Dis. 2011;203:1791-1801
24. Mondy K, Yarasheski K, Powderly WG, et al. Longitudinal evolution of bone mineral density and bone markers in human immunodeficiency virus-infected individuals. Clin Infect Dis. 2003;36:482-490
25. Nolan D, Upton R, McKinnon E, et al. Stable or increasing bone mineral density in HIV-infected patients treated with nelfinavir or indinavir. AIDS. 2001;15:1275-1280
26. Mundy LM, Youk AO, McComsey GA, et al. Overall benefit of antiretroviral treatment on the risk of fracture in HIV: nested case-control analysis in a health-insured population. AIDS. 2012;26:1073-1082
27. Grant PM, Kitch D, McComsey GA, et al. Low baseline CD4+ count is associated with greater bone mineral density loss after antiretroviral therapy initiation. Clin Infect Dis. 2013;57:1483-1488
28. Moyle G, Hardy H, Uy J, et al. Changes in biomarkers in HIV-1-infected treatment-naive patients treated with tenofovir DF/emtricitabine plus atazanavir/ritonavir or lopinavir/ritonavir for 96 weeks: the CASTLE biomarker substudy. Antivir Ther. 2014. [Epub ahead of print].
29. Reid IR. Relationships between fat and bone. Osteoporos Int. 2008;19: 595-606
30. Sharma A, Tian F, Yin MT, et al. Association of regional body composition with bone mineral density in HIV-infected and HIV-uninfected women: womens interagency HIV study. J Acquir Immune Defic Syndr. 2012;61:469-476
31. Moyle GJ, Hardy H, Farajallah A, et al. Comparison of body composition changes between atazanavir/ritonavir and lopinavir/ritonavir each in combination with Tenofovir/Emtricitabine in antiretroviralnaive patients with HIV-1 infection. Clin Drug Investig. 2014;34: 287-296
32. Kearney BP, Mathias A, Mittan A, et al. Pharmacokinetics and safety of tenofovir disoproxil fumarate on coadministration with lopinavir/ritonavir. J Acquir Immune Defic Syndr. 2006;43:278-283
33. Kiser JJ, Carten ML, Aquilante CL, et al. The effect of lopinavir/ritonavir on the renal clearance of tenofovir in HIV-infected patients. Clin Pharmacol Ther. 2008;83:265-272
34. Bristol-Myers Squibb Company. Prescribing Information for Reyataz (Atazanavir). Available at: http://packageinserts.bms.com/pi/pi-reyataz.pdf. Accessed June 24, 2014
35. Baxi SM, Greenblatt RM, Bacchetti P, et al. Common clinical conditions-age, low BMI, ritonavir use, mild renal impairment-affect tenofovir pharmacokinetics in a large cohort of HIV-infected women. AIDS. 2014; 28:59-66
36. Zhu L, Liao S, Child M, et al. Pharmacokinetics and inhibitory quotient of atazanavir/ritonavir versus lopinavir/ritonavir in HIV-infected, treatmentnaive patients who participated in the CASTLE Study. J Antimicrob Chemother. 2012;67:465-468
37. Parks DA, Jennings HC, Taylor C, et al. Steady-state amprenavir, tenofovir, and emtricitabine pharmacokinetics before and after reducing ritonavir boosting of a fosamprenavir/tenofovir/emtricitabine regimen from 200 mg to 100 mg once daily (TELEX II). HIV Clin Trials. 2009;10: 160-167
38. Hernandez-Vallejo SJ, Beaupere C, Larghero J, et al. HIV protease inhibitors induce senescence and alter osteoblastic potential of human bone marrow mesenchymal stem cells: beneficial effect of pravastatin. Aging Cell. 2013;12:955-965.